EUVIMEDScopri EUVIMED
Open access · CC BY-NC-ND 4.0

Type I and II Interferons Drive Abacavir Hypersensitivity via Treg Suppression and T‐Cell Enhancement in Immunocompetent HLA ‐Transgenic Mice

SuJin Hwang iD, Telly Sepahpour, Stephanie Kortchak, Kirthiram Krishnaveni Sivakumar, Spyros Karaiskos, Ngoc Pham, Yura Jang, Montserrat Puig, Michael Norcross

Allergy · 2026

DOI: 10.1111/all.70189 ↗

At a glance

Journal article in Allergy, 2026. Written by SuJin Hwang and 8 co-authors. Institution: Division of Product Quality Research 4, Office of Product Quality Research, Office of Product Quality, Center for Drug Evaluation and Research, U.S. …. Major MEDLINE topics: Dideoxynucleosides, T-Lymphocytes, Regulatory, Drug Hypersensitivity, Interferon Type I. Cited 2 times so far (Crossref); 47 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: U.S. Food and Drug Administration, Oak Ridge Institute for Science and Education (ORISE).

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Background

Abacavir (ABC)‐induced hypersensitivity is associated with HLA‐B*57:01, with tolerance maintained by regulatory T cells (Treg). This study hypothesized that the balance between Treg and CD8 + T‐cells is influenced by the level of human leucocyte antigen (HLA) expression to determine hypersensitivity versus tolerance to abacavir.

Methods

HLA‐B*57:01 transgenic (Tg) mice and Tg mice lacking H2‐K b D b (Tg/KO) were treated with ABC with or without IFN‐α or IFN‐γ blockade. Immune cell phenotype and functions were assessed via flow cytometry, and splenic transcriptomic profiles were analyzed to evaluate gene expression changes associated with treatment.

Results

ABC treatment of Tg/KO mice, which only express HLA‐B*57:01 as an MHC‐I allele, led to the expansion of drug‐specific CD8 + T‐cells, enhanced antigen presenting cell (APC) activity, and reduction in Tregs. These changes were accompanied by increased IFN‐α levels and plasmacytoid dendritic cell (pDC) maturation. Depletion of pDCs or blocking of IFN‐αR, in contrast to IFN‐γ blockade, restored Treg populations and diminished CD8 + T‐cell responses. These findings demonstrate that IFN‐α, primarily produced by pDCs, disrupts Treg expansion, whereas IFN‐γ predominantly enhances APC maturation and activation. Transcriptomic analysis revealed key genes regulated exclusively by ABC treatment in the presence of both IFN‐α and IFN‐γ signaling and demonstrated that IFN‐α signaling predominantly modulates innate and adaptive immune genes while supporting the downregulation of Treg‐related genes.

Conclusions

In vivo upregulation of HLA expression modulates the balance between drug‐specific and regulatory T cells, thereby promoting optimal pDC expansion and enhancing IFN‐α production, which counteracts Treg‐mediated ABC tolerance. IFN‐γ secretion by drug‐specific CD8 + T‐cells promoted APC and effector T‐cell function that led to the development of ABC‐associated hypersensitivity reactions in immunocompetent HLA Tg mice.

Subjects

MeSH terms (MEDLINE)

DideoxynucleosidesT-Lymphocytes, RegulatoryDrug HypersensitivityInterferon Type IHLA-B AntigensAnimalsAbacavirMice, TransgenicMiceHumansDendritic CellsCD8-Positive T-LymphocytesInterferon-gammaDisease Models, Animal

Author keywords

HLA‐B*57:01IFN‐αIFN‐γabacavir hypersensitivity reaction (AHR)plasmacytoid DCregulatory T‐cells

Substances

AbacavirDideoxynucleosidesInterferon Type IInterferon-gammaHLA-B Antigens

Authors and institutions

  • Division of Product Quality Research 4, Office of Product Quality Research, Office of Product Quality, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
  • Office of Biostatistics and Pharmacovigilance, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.

ORCID profiles: SuJin Hwang

Funding

  • U.S. Food and Drug Administration
  • Oak Ridge Institute for Science and Education (ORISE)

Cite

APA

Hwang, S., Sepahpour, T., Kortchak, S., Sivakumar, K. K., Karaiskos, S., Pham, N., Jang, Y., Puig, M., & Norcross, M. (2026). Type I and II Interferons Drive Abacavir Hypersensitivity via Treg Suppression and T‐Cell Enhancement in Immunocompetent HLA ‐Transgenic Mice. Allergy. https://doi.org/10.1111/all.70189

Vancouver

Hwang S, Sepahpour T, Kortchak S, Sivakumar KK, Karaiskos S, Pham N, et al. Type I and II Interferons Drive Abacavir Hypersensitivity via Treg Suppression and T‐Cell Enhancement in Immunocompetent HLA ‐Transgenic Mice. Allergy. 2026. doi:10.1111/all.70189

BibTeX
@article{Hwang2026,
  author = {Hwang, SuJin and Sepahpour, Telly and Kortchak, Stephanie and Sivakumar, Kirthiram Krishnaveni and Karaiskos, Spyros and Pham, Ngoc and Jang, Yura and Puig, Montserrat and Norcross, Michael},
  title = {Type I and II Interferons Drive Abacavir Hypersensitivity via Treg Suppression and T‐Cell Enhancement in Immunocompetent HLA ‐Transgenic Mice},
  journal = {Allergy},
  year = {2026},
  doi = {10.1111/all.70189}
}
Start for free →